Title
Category
Credits
Event date
Cost
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
During this Masterclass, expert faculty will discuss the links between sleep disorders and cardiometabolic health, as well as practical approaches for screening, referral, or treatment.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
Osteoporosis is a prevalent condition and a major health problem, but particularly more in postmenopausal women. Approximately 2 million osteoporosis-related fractures occur annually in the US, and more than 70% of these occur in women. Furthermore, osteoporosis carries a significant burden, estimated to be at $57 billion in 2018 and projected to reach more than $95 billion by year 2040.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
Patients with diabetes and PAD, particularly those with concomitant polyvascular disease, are at a greater risk for future adverse cardiovascular and limb events.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
Several cardiometabolic comorbidities, including overweight/obesity, dyslipidemia, cardiovascular diseases, hypertension, and type 2 diabetes or insulin resistance, are common in patients with narcolepsy.  Often these disorders are overlooked, but they have important implications in the management of  these patients.  Some medications used to treat symptoms of narcolepsy may have potential negative effects on cardiovascular health, including in patients that are sensitive to sodium, such as those with hypertension, heart failure, or impaired renal function.  However, long-term data on the c
  • LivDerm
  • TME
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Within the past decade, aesthetic medicine –particularly minimally invasive aesthetic practice – has significantly advanced. An increasingly common cultural emphasis on beauty and health has resulted in a surge in anti-aging technologies, minimally invasive aesthetic procedures and cosmeceuticals aimed at helping individuals achieve sprightly appearances with healthy skin.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
By now, it is established that the burden of cardiometabolic risk, including CVD, diabetes, atherosclerosis, hypertension, obesity, and more, are higher in certain racial and ethnic minorities, including African Americans, Latinos, and Native Americans. As such, it is by no means a coincidence that the burden of COVID-19 morbidity and mortality is disproportionate towards these communities, stemming not only from a higher prevalence of these comorbidities, but also from socioeconomic factors.

Pages